Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Horizon Pharma To Buy Vidara For $660M

By Pharmaceutical Processing | March 19, 2014

DEERFIELD, Ill. (AP) — Horizon Pharma Inc. plans to buy the privately held Vidara Therapeutics International Ltd. in a cash-and-stock deal that will add the immune system disorder drug Actimmune to the specialty drugmaker’s product portfolio.

Shares of Horizon soared in premarket trading Wednesday after the Deerfield, Ill., company said it will pay about $660 million in a deal that creates an Ireland-based company named Horizon Pharma PLC.

Vidara shareholders will receive $200 million in cash and retain about a 26 percent stake in Horizon Pharma PLC.

Horizon Chairman and CEO Timothy P. Walbert will keep those titles with the combined company.

Vidara has operations in both Dublin and the United States. It bought Actimmune from InterMune Inc. in 2012 for $55 million. The drug tallied nearly $59 million in sales for Vidara last year.

Walbert said in a statement that the addition of Actimmune complements his company’s business model, which focuses on promotions to primary care doctors and specialists. Horizon’s portfolio already includes Vimovo, which is approved as a treatment for symptoms of osteoarthritis and rheumatoid arthritis.

The company also said the deal gives it a “tax efficient corporate structure” to support growth and acquisitions.

Horizon said the boards of both companies have unanimously approved the acquisition, which is expected to close in the middle of the year.

Shares of Horizon were up nearly 20 percent, or $2.92, to $17.60 in premarket trading more than an hour before markets opened Wednesday. That would easily top the company’s all-time high price during regular trading of $14.75, which the stock reached Tuesday.

The shares have nearly doubled in value since closing 2013 at $7.62.

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards